Oncovita is a biotechnology company specializing in the development of innovative treatments for cancer. The company leverages its proprietary technology platform, which is based on the use of recombinant measles virus, to create targeted oncolytic virotherapies. Oncovita's approach aims to harness the potential of virotherapy to selectively destroy cancer cells while sparing healthy tissues.

Oncovita

OncoVITA is a biotechnology company based out of 28 RUE DU DOCTEUR ROUX, PARIS, France.

OncoVITA

OncoVITA raised $8,741,000-Congrats Jean-Francois Le Bigot, PhD
Full Round Info: https://lnkd.in/gpVkW8CT
Round Investors: Private Investors and Business Angels

Oncovita raise 8M€ to support the development of its MVdeltaC immunotherapeutic vaccine in oncology

#MONEYTIME 
OncoVITA décroche 8M€ de financements. Cette biotech francilienne, spin-off de l’Institut Pasteur, cible les tumeurs solides avec MVdeltaC un candidat vaccin immuno-thérapeutique utilisant le virus de la rougeole. Dirigée par Jean-Francois Le Bigot, PhD  (ex-Citoxlab), Oncovita a collecté 4,5 M€ en subvention et prêt dans le cadre du plan d’investissement France 2030 opéré par Bpifrance et 3,5 M€ en provenance d’investisseurs privés. Les fonds permettront notamment la production d’un premier lot clinique de MVdeltaC, puis l’initiation d’un essai clinique de phase 1/2a dans des tumeurs solides courant 2025. Plus d’infos dans #BiotechFinances n°1050 à paraître ce vendredi. 

#AnnonceWebinaire  : mardi 5 décembre à 19H avec Pierre D’EPENOUX (CEO d’IMCHECK) et Marina ICHÉ (CEO d’ILIFE). "ImCheck & ILife : le développement clinique, pilier du succès !" La stratégie clinique et son exécution opérationnelle dans la biotech. L’exemple d’ImCheck Therapeutics, en dialogue avec son partenaire de la 1ère heure, ILife Consulting. Inscription gratuite : https://lnkd.in/eUNuNUdr
 
#BioMapFrance2024. N'oubliez pas de remplir le formulaire avant le 31/12/2023 pour figurer gratuitement sur le poster BioMap France 2024 qui sera publié en janvier prochain ! Lien : https://lnkd.in/efGVY8Mp


Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells
Cancer Immunol Immunother. 2023 Oct;72(10):3309-3322. 

In this study, we show that the attenuated Schwarz MV encoding human NY-ESO-1 is able to express this tumor antigen in infected melanoma tumor cells, while retaining its oncolytic activity. Upon infection of melanoma cells, NY-ESO-1 is strongly expressed and NY-ESO-1 peptides are efficiently presented by infected tumor cells to specific CD8 + and CD4 + T cells by HLA class I and II molecules. We also show that MVny replicates modestly in monocyte-derived DCs compared to melanoma cells, allowing DCs to present NY-ESO-1 peptides to specific CD4 + and CD8 + T cells. Altogether, these results demonstrate that MVny displays an oncolytic activity against melanoma cell lines and induces NY-ESO-1 peptides presentation not only by tumor cells, but also by antigen presenting cells such as monocyte-derived DCs.


Metric
Company Name	Oncovita
Symbol
MSH ID	FR:ONCOVITA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	FR
Stage
Employee Count	5
Website	oncovita.fr
LinkedIn	oncovita
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

FR:ONCOVITA

Oncovita

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue